bioAffinity Technologies, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
bioAffinity Technologies, Inc. (BIAF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-04-01
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares.
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 0.00 shares.
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 0.00 shares.
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 7.14K shares, a 90.99% decline from fiscal 2021.
- bioAffinity Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 79.27K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 0.00 shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 0.00 shares derived: sum of 2 quarters · filed 2024-04-01 | 0.00 shares derived: sum of 3 quarters · filed 2024-04-01 | 7.14K shares 10-K · filed 2024-04-01 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-14 | 7.14K shares 10-Q · filed 2023-11-14 | 57.14K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 7.14K shares 10-Q · filed 2023-08-14 | 57.14K shares derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | 7.14K shares 10-Q · filed 2023-05-15 | 57.14K shares derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | 49.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 79.27K shares 10-K · filed 2023-03-31 | ||
| 2021-09-30 | 29.28K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |